Pierre  Busson
  • E-mail :[email]
  • Phone : +33632444926
  • Location : Villejuif, France
Last update 2018-06-05 22:51:37.831

Pierre Busson MD, PhD, ScD, CNRS Director of research

Course and current status

Dr. Pierre BUSSON, MD, PhD, ScD

 CNRS director of Research (DR2 CNRS) - Born on July 29, 1956

 Team “Tumor microenvironment, exosomes and microRNAs in solid tumors”.                                                                                                            Certified by AERES/HCERES in 2010 and 2015.

UMR 8126 – CNRS/Gustave Roussy                                                                                                                   94805 Villejuif – FRANCE - Tel: +33 1 42 11 45 83                                                                                                                 Email: Pierre.BUSSON@gustaveroussy.fr

Orcid number : 0000-0003-1027-3400

 

 Education     

2001 Certification of supervisory ability (HDR – ScD)

1990  PhD in Biochemistry/Virology – University of Paris VII

1983 - 1984   Master of Biochemistry and certificate of General Virology (Pasteur Institute)         

1973-1983     Medical Studies (Pierre et Marie Curie University, Paris)

 

Professional cursus

2008               CNRS director of Research (DR2) – Gustave Roussy   

1992-2007     CNRS researcher- Gustave Roussy

1990-1992     Post-doc, University of North Carolina, Chapel Hill, USA     

1983-1989     PhD student including 2 years as Inserm junior researcher (1988-89)

1979-1983     Paris Hospital residency (radiotherapy, critical care medicine, oncology)

 

Awards

2015: Co-recipient of the Matwin 2015 award for the "best project answering an unmet medical need"

2012: excellence premium awarded by the Centre National de la Recherche Scientifique (CNRS)

2011: entitled with a Translational Research hospital convention (Aviesan)

 

Publications 95 publications - 6253 citations including 2059 since 2013 - H index 43 (23 since 2013)(Google scholar).

 

Patents  

 PCT/IB03/04922 - PCT/FR2009/000409 - PCT/FR12/000550

W0 2015/185875 A2 - 50% of the inventive parts for our team - licensed to the company H-Immune Therapeutics since February 2017.

Recent Funding

 INCa-DGOS grant for translational research, 2017-2020

Bristol-Myers-Squibb Foundation for Research in Immuno-Oncology, 2017 and 2018

Incentive grant from Idex Paris-Saclay (Health Sciences Dpt), 2017

Prematuration grant from Idex Paris-Saclay, 2015-2016

Teaching activities

 In charge of a 20 hour course on « Infectious agents and human Cancers » since 2005 (Master 2 of Oncology at Paris-Saclay university)

Various teaching activities at Gustave Roussy and Pasteur institutes.

 Scientific supervision

Sixteen master 2 students

Thirteen PhD students: 10 theses completed (one in 1994, 2001, 2005, two in 2009, one in 2011, two in 2013, one in 2015, 2016, 2017) – 2 theses in progress.

Six post-doctoral researchers (1994-95, 1998, 2000-2001, 2003-2004, 2014-15, 2017-2018)

Research animation and management

 Elected member of the Research governing board at  Gustave Roussy from 2006 to 2009

Member of the steering committee of the « Herpesvirus and Cancer network» from 2006 to 2010

Organizer and/or scientific committee member for preparation of international workshops on Nasopharyngeal Carcinoma from 2003 to 2015.

Member of the organizing committee and “Session discussion leader" for the first Gordon Conference on Nasopharyngeal Carcinoma (Hong Kong, June 2016).

Speaker at the second Gordon Conference on Nasopharyngeal Carcinoma (Hong Kong, June 2017).

Editorial activity  

 Academic editor for Plos-One since 2011

Member of the editorial board for Frontiers in Immunology (section Tumor Immunity)

Ad hoc reviewer for various international scientific journals (JNCI, Blood, PNAS, Cancer Research, Journal of Virology, Oncogene, Journal of Pathology, American Journal of Pathology etc…)

 

Research assessment and expertise  

External reviewer for the Research Grants Council of Hong-Kong (2003 to 2018), FRS/FNRS (Belgium 2012 to 2018), Paris-Hospitals (2005, 2007, 2013), French National Research Agency (ANR 2010 to 2012) and various public and private funding bodies in France and abroad  (Bloodwise, UK; Cancer Research UK; KWF Kankerbestrijding, Holland; Aquitaides; Alsace-Biovalley; Cancéropôle-Ile de France; Clara; Comue Grenoble-Alpes; Finovi; Gefluc; Ligue Nationale contre le Cancer; Société Française de Dermatologie).

Scientific summary

Our main current project is to investigate the immunosuppressive effects of galectin-9, a protein often released by tumor cells from various types of human malignancies. Simultaneously, we produce, characterize and develop therapeutic monoclonal antibodies aiming at neutralization of galectin-9 and restoration of anti-tumor immunity (patent W0 2015/185875 A2; project accredited by the French MATWIN board on May 2015).

We also investigate circulating tumor microRNAs as a source of biomarkers for several human malignancies, especially ovarian carcinomas. We have shown that the positive or negative variations of miR200b concentration in the plasma, before and after the primary treatment of ovarian carcinomas, are predictive of the disease-free survival.

Image d’exemple